
DWTX Stock Forecast & Price Target
DWTX Analyst Ratings
Bulls say
Dogwood Therapeutics Inc. has raised its 12-month price target from $10.00 to $12.00, reflecting optimism regarding the future revenue potential associated with new product assets and strategic partnerships. The company's recent licensing agreement with Serpin Pharma for the global rights to SP16 reinforces its commitment to developing therapies that address significant unmet medical needs, particularly in cancer-related pain. Additionally, Dogwood's focus on innovative antiviral therapies positions it favorably within the biotechnology sector, enhancing prospects for future growth.
Bears say
Dogwood Therapeutics Inc, previously known as Virios Therapeutics Inc, faces challenges in advancing its antiviral therapies, particularly in addressing diseases linked to viral-triggered immune responses. The company's product candidates, IMC-1 and IMC-2, are in the development stage, which inherently involves significant risks and uncertainties regarding their commercial viability and potential regulatory hurdles. Additionally, the lack of established market presence and competition within the biotechnology sector raises concerns about the firm's ability to secure necessary funding and achieve sustainable growth.
This aggregate rating is based on analysts' research of Dogwood Therapeutics, Inc. and is not a guaranteed prediction by Public.com or investment advice.
DWTX Analyst Forecast & Price Prediction
Start investing in DWTX
Order type
Buy in
Order amount
Est. shares
0 shares